title: Inversion and deletion of 16q22 defined by array CGH, FISH, and RT-PCR in a patient with AML.
abstract: Acute myelomonocytic leukemia with eosinophilia is commonly associated with pericentric inversions of chromosome 16, involving the core binding factor beta gene (CBFB) on 16q22 and the myosin heavy chain gene (MYH11) on 16p13. The inv(16)(p13q22) results in a fusion gene comprising the 5'CBFB gene and the 3'MYH11 gene on the short arm of chromosome 16. The fusion gene interferes with the normal transcription of the CBFA/CBFB heterodimer and disrupts myeloid differentiation. The inv(16) is associated with a good prognosis. The inv(16) with deletion of the 3'CBFB region of the gene is a very rare occurrence. Although the number of cases is small, inv(16) with a deleted 3'CBFB seems to be associated with a poorer prognosis than that generally associated with inv(16). Our patient was a 30-year-old man with newly diagnosed acute myeloid leukemia who was found to have a CBFB-MYH11 fusion by reverse transcriptase-polymerase chain reaction. The high blast count and lack of differentiation were not typical for this entity and suggested clonal progression. The initial karyotype by conventional cytogenetic analysis, in all metaphases examined, was 46,XY,del(7)(q32),del(16)(q22). Fluorescence in situ hybridization analysis with a dual-color, break-apart probe corresponding to the CBFB gene locus (Abbott, Des Plaines, IL) showed a derivative chromosome 16 resulting from an inversion of the CBFB gene with a deletion of the 3'CBFB probe region. Oligonucleotide array comparative genetic hybridization analysis was performed on this patient's diagnostic bone marrow DNA referenced to a normal male control DNA by using the DNAarray Heme Profile (CombiMatrix Diagnostics, Irvine, CA) microarray. This analysis showed a 1.2 Mb loss of 16q22.1, which did not include loss of the 3'CBFB gene locus, but rather sequences distal to this locus. The DNAarray Heme Profile results illustrate the importance of microarray in the correct identification of abnormalities that will affect prognosis.
authors.affiliation: Cytogenetic Laboratory, Diagnostic Services of Manitoba, Health Sciences Centre, Winnipeg, Canada. adawson@hsc.mb.ca
authors.forename: Angelika J
authors.initials: AJ
authors.lastname: Dawson
authors.forename: Shibani
authors.initials: S
authors.lastname: Bal
authors.forename: Barry
authors.initials: B
authors.lastname: McTavish
authors.forename: Michelle
authors.initials: M
authors.lastname: Tomiuk
authors.forename: Ingo
authors.initials: I
authors.lastname: Schroedter
authors.forename: Arshad N
authors.initials: AN
authors.lastname: Ahsanuddin
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Seftel
authors.forename: Rhea
authors.initials: R
authors.lastname: Vallente
authors.forename: Sabine
authors.initials: S
authors.lastname: Mai
authors.forename: Philip D
authors.initials: PD
authors.lastname: Cotter
authors.forename: Karine
authors.initials: K
authors.lastname: Hovanes
authors.forename: Mercedes
authors.initials: M
authors.lastname: Gorre
authors.forename: Shelly R
authors.initials: SR
authors.lastname: Gunn
mesh_terms: D000328:Adult; D002872:Chromosome Deletion; D007446:Chromosome Inversion; D002885:Chromosomes, Human, Pair 16; D055028:Comparative Genomic Hybridization; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D008297:Male; D020133:Reverse Transcriptase Polymerase Chain Reaction